A solid year for net asset value

Polar Capital Global Healthcare Trust (LSE:PCGH), the FTSE 250 specialist healthcare Investment trust, closed its financial year on 30 September in a much firmer position than a year earlier. Its latest daily valuation put unaudited cum-income NAV at 425.90p per share at the close on 7 October, up from 422.66p a day earlier. At the end of the previous financial year, on 30 September 2025, NAV per share was 369.51p, so the portfolio has gained substantially over the past twelve months as healthcare shares recovered from a weak 2024–25.

That rebound followed a significant restructuring. In late 2025 shareholders approved proposals that removed the trust's fixed end date and extended its life indefinitely. They also introduced a tiered management fee of 0.70% on the first £500m of Assets and 0.65% above that, and scrapped the performance fee. As part of the package, 22.47% of the Share Capital was tendered and bought back at 425.61p. After the tender the trust has 107,950,000 shares with voting rights, with 16,199,256 held in treasury.

Inside the portfolio

A disclosure on 5 October set out the portfolio at 30 September. The ten largest holdings made up 55.7% of the fund. Johnson & Johnson was the biggest position at 10.1%, followed by Eli Lilly at 9.8% and UnitedHealth Group at 6.1%. The rest of the top ten was Roche, Teva Pharmaceutical, Abbott Laboratories, Danaher, AstraZeneca, Agilent Technologies and IQVIA.

By sub-sector, pharmaceuticals made up 40.2% of the portfolio and biotechnology 19.4%. Life sciences tools and services and healthcare equipment each accounted for about 13%, and managed healthcare for 8.5%. The United States made up 71.8% of exposure, followed by the UK at 6.4% and Switzerland at 5.6%. A negative cash position of 8.4% shows the trust is using some borrowing to increase its market exposure.

Sector drivers and what comes next

Large pharmaceutical companies have been central to the healthcare recovery. Demand for obesity and diabetes treatments continues to support Eli Lilly, while Takeover activity has picked up across biotechnology as large drugmakers seek to replace Revenue lost when patents expire. Health insurers such as UnitedHealth have faced cost pressures and US policy uncertainty. Drug pricing reform in the United States remains a risk for the wider sector.

Co-managers James Douglas and Gareth Powell have said they see solid industry fundamentals and attractive valuations relative to the wider Equity market, and the board has described itself as very optimistic about the sector. The annual results for the year just ended, expected in the coming months, will show how NAV and share price returns compared with the MSCI ACWI Healthcare benchmark. They will also show the discount at the year end and how the trust has used its new open-ended life and fee structure.

Investors will also want to see whether the trust can return to its earlier record of beating the benchmark. In the year to September 2025 NAV fell 5.86%, but the trust still outperformed the MSCI ACWI Healthcare index by nearly two percentage points. The annual Dividend that year was 2.20p, so income is only a small part of total returns.

For now, the daily NAV figures and the concentrated top ten suggest a portfolio leaning towards established, cash-generative healthcare businesses, with a smaller allocation to higher-risk biotechnology.